NASDAQ:TENX - Tenax Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.41 +0.02 (+0.31 %)
(As of 06/24/2018 06:36 AM ET)
Previous Close$6.41
Today's Range$6.35 - $6.49
52-Week Range$4.40 - $15.80
Volume6,040 shs
Average Volume19,555 shs
Market Capitalization$9.29 million
P/E RatioN/A
Dividend YieldN/A
Beta1.62
Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Receive TENX News and Ratings via Email

Sign-up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TENX
CUSIPN/A
Phone919-855-2100

Debt

Debt-to-Equity RatioN/A
Current Ratio22.55
Quick Ratio22.55

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$40,000.00
Price / Sales232.36
Cash FlowN/A
Price / CashN/A
Book Value$6.29 per share
Price / Book1.02

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-8,830,000.00
Net MarginsN/A
Return on Equity-70.29%
Return on Assets-63.13%

Miscellaneous

Employees8
Outstanding Shares1,450,000

The Truth About Cryptocurrencies

Tenax Therapeutics (NASDAQ:TENX) Frequently Asked Questions

What is Tenax Therapeutics' stock symbol?

Tenax Therapeutics trades on the NASDAQ under the ticker symbol "TENX."

When did Tenax Therapeutics' stock split? How did Tenax Therapeutics' stock split work?

Tenax Therapeutics's stock reverse split on Monday, February 26th 2018. The 1-20 reverse split was announced on Friday, February 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 23rd 2018. An investor that had 100 shares of Tenax Therapeutics stock prior to the reverse split would have 5 shares after the split.

How were Tenax Therapeutics' earnings last quarter?

Tenax Therapeutics Inc (NASDAQ:TENX) released its quarterly earnings data on Tuesday, December, 15th. The specialty pharmaceutical company reported ($2.60) earnings per share for the quarter, topping the Zacks' consensus estimate of ($2.80) by $0.20. View Tenax Therapeutics' Earnings History.

Who are some of Tenax Therapeutics' key competitors?

Who are Tenax Therapeutics' key executives?

Tenax Therapeutics' management team includes the folowing people:
  • Mr. Anthony A. DiTonno, CEO & Director (Age 70)
  • Mr. Michael B. Jebsen, Pres & CFO (Age 47)
  • Mr. John P. Kelley, Consultant (Age 64)
  • Ms. Nancy J. M. Hecox, Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.
  • Maria Isabel Tomargo, Assistant VP of Marketing & Sales

Has Tenax Therapeutics been receiving favorable news coverage?

Press coverage about TENX stock has been trending somewhat positive on Sunday, Accern reports. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tenax Therapeutics earned a news impact score of 0.13 on Accern's scale. They also assigned news stories about the specialty pharmaceutical company an impact score of 44.16 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Tenax Therapeutics' major shareholders?

Tenax Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Financial Advisory Service Inc. (4.04%). Company insiders that own Tenax Therapeutics stock include Gerald T Proehl and Ronald R Blanck. View Institutional Ownership Trends for Tenax Therapeutics.

Which institutional investors are selling Tenax Therapeutics stock?

TENX stock was sold by a variety of institutional investors in the last quarter, including Financial Advisory Service Inc.. View Insider Buying and Selling for Tenax Therapeutics.

How do I buy shares of Tenax Therapeutics?

Shares of TENX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tenax Therapeutics' stock price today?

One share of TENX stock can currently be purchased for approximately $6.41.

How big of a company is Tenax Therapeutics?

Tenax Therapeutics has a market capitalization of $9.29 million and generates $40,000.00 in revenue each year. Tenax Therapeutics employs 8 workers across the globe.

How can I contact Tenax Therapeutics?

Tenax Therapeutics' mailing address is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. The specialty pharmaceutical company can be reached via phone at 919-855-2100 or via email at [email protected]


MarketBeat Community Rating for Tenax Therapeutics (TENX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  81 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  133
MarketBeat's community ratings are surveys of what our community members think about Tenax Therapeutics and other stocks. Vote "Outperform" if you believe TENX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TENX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.